Rheumatology is the branch of medicine devoted to diagnosing and treating diseases of the joints, muscles, bones, and connective tissues, with a particular focus on conditions driven by immune system dysfunction. The word itself traces back to the Greek “rheuma,” meaning “flowing,” a reference to the ancient belief that disease resulted from fluids flowing through the body. Though the concept is ancient, rheumatology only became a recognized medical specialty in the twentieth century, and the term “rheumatologist” was coined by American physicians Bernard Comroe and Joseph Lee Hollander in 1940.1Medical Journal of Dr D Y Patil University. History of rheumatology What surprises many people is how far the specialty reaches beyond sore joints.
What a Rheumatologist Actually Does
If you picture a rheumatologist as a doctor who treats arthritis and nothing else, the reality is much broader. Rheumatologists are internists (or pediatricians) who complete additional fellowship training in diseases where the immune system attacks the body’s own tissues or where chronic inflammation damages organs. That includes more than a hundred distinct conditions. Some, like rheumatoid arthritis, are household names. Others, like systemic vasculitis or scleroderma, are rare enough that most people have never heard of them.
The common thread across these diseases is that the immune system is doing something it shouldn’t. In some cases it produces antibodies that target the body’s own cells. In others, the inflammatory machinery fires without a clear trigger. A rheumatologist’s training is built around untangling which of these processes is causing a patient’s symptoms and choosing the right treatment to dial it down.
The Conditions Rheumatology Covers
The diseases under the rheumatology umbrella fall into several broad families, and understanding these groupings helps explain why the specialty exists as a distinct field rather than being folded into orthopedics or general internal medicine.
Inflammatory Arthritis
Rheumatoid arthritis is the flagship condition. It involves persistent inflammation of the synovial membrane, the thin lining inside joints. Over time, this inflammation produces an invasive tissue called pannus that gradually destroys cartilage, bone, and surrounding soft tissue.2PubMed Central. The pathogenesis of rheumatoid arthritis in radiological studies. Part I: Formation of inflammatory infiltrates within the synovial membrane The pannus doesn’t just sit there passively; it actively invades cartilage and bone while releasing molecules that amplify inflammation further.3PubMed. Pathogenesis of joint destruction in rheumatoid arthritis Globally, rheumatoid arthritis affects roughly one in four hundred people, and its burden on disability has grown over recent decades primarily because populations are aging.4Annals of the Rheumatic Diseases. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
Ankylosing spondylitis is another major inflammatory arthritis, but it targets the spine and pelvis rather than the small joints of the hands. It has a strong genetic component, particularly the HLA-B27 gene. People who carry HLA-B27 are at considerably higher risk for the disease, though having the gene doesn’t guarantee you’ll develop it. Researchers have identified several ways HLA-B27 may contribute: the protein it encodes folds unusually slowly, and misfolded copies can pile up inside cells and trigger inflammatory signaling pathways.5PubMed Central. HLA-B27 misfolding and ankylosing spondylitis HLA-B27 molecules can also form abnormal pairs called homodimers that activate immune cells in the gut and joints.6Bone Research. Ankylosing spondylitis: etiology, pathogenesis, and treatments The connection between HLA-B27 and spondyloarthropathies remains one of the strongest gene-disease associations known in medicine.7PubMed. HLA-B27 and the pathogenesis of spondyloarthropathies
Systemic Autoimmune Diseases
Some rheumatic conditions don’t stay in the joints at all. Systemic lupus erythematosus is a prime example: it can cause inflammatory damage across the kidneys, skin, central nervous system, and blood cells. The hallmark of lupus is a broad array of autoantibodies, with anti-dsDNA and anti-Sm antibodies being particularly specific to the disease.8PubMed. Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target Patients with lupus who develop blood-related complications tend to be more likely to show pulmonary lesions and spleen enlargement as well, reflecting just how widespread the disease’s reach can be.9PubMed Central. Analysis of multiple organ damage and clinical immunological characteristics in systemic lupus erythematosus patients with hematologic involvement
Other systemic conditions in the rheumatologist’s territory include Sjögren’s syndrome (which attacks moisture-producing glands), systemic sclerosis (which causes hardening and thickening of the skin and internal organs), and various forms of vasculitis (inflammation of blood vessels). What unites these diseases is that they require someone who can think across organ systems rather than focusing on just one.
Crystal-Induced Arthritis
Gout is probably the oldest known rheumatic disease, described in medical texts for millennia. It results from deposits of monosodium urate crystals in and around joints, which trigger a specific inflammatory alarm system called the NLRP3 inflammasome, leading to sudden intense flares of joint pain.10PubMed Central. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout One puzzling feature of gout is that many people with elevated uric acid levels in their blood never develop clinical disease, which suggests that crystal deposition alone doesn’t tell the whole story.11PubMed Central. Uric Acid as a Redox Switch in Gout: Linking Xanthine Oxidoreductase-Derived ROS, NLRP3 Inflammasome Activation and Emerging Ferroptotic Mechanisms Pseudogout, caused by calcium pyrophosphate crystals rather than urate, follows a similar pattern of acute flares but tends to affect different joints, most commonly the knees and wrists.
Osteoarthritis and Other Non-Autoimmune Conditions
Osteoarthritis was long considered a purely “wear and tear” problem, not an immune-mediated disease. That view has shifted. Researchers now recognize that low-grade inflammation plays a central role in osteoarthritis progression, and the condition has recently been reclassified as a low-grade inflammatory disease of the joint.12PubMed Central. Low-Grade Inflammation in the Pathogenesis of Osteoarthritis: Cellular and Molecular Mechanisms and Strategies for Future Therapeutic Intervention Obesity, aging, and metabolic disorders all feed into this inflammatory process, which helps explain why osteoarthritis is so strongly associated with those risk factors. Even though osteoarthritis doesn’t involve the dramatic immune attacks seen in rheumatoid arthritis, many patients with severe or atypical cases end up seeing a rheumatologist.
Autoimmune Versus Autoinflammatory
One distinction that shapes modern rheumatology is the difference between autoimmune and autoinflammatory diseases. In autoimmune diseases, the adaptive immune system (the branch that makes targeted antibodies and learns to attack specific threats) turns on the body’s own tissues. Lupus, rheumatoid arthritis, and myositis fall into this category. In autoinflammatory diseases, the innate immune system (the first-response, less specific branch) fires without a proper trigger, producing episodes of inflammation without the high levels of autoantibodies that characterize autoimmune conditions.13The Egyptian Journal of Internal Medicine. Bridging autoinflammatory and autoimmune diseases Gout sits squarely in the autoinflammatory camp. A growing number of rare hereditary fever syndromes do as well.
In practice, many diseases don’t fit neatly into one box. Ankylosing spondylitis has features of both. So does psoriatic arthritis. This blurring has pushed rheumatologists to think less in rigid categories and more along a spectrum of immune dysfunction, which has opened doors to using treatments developed for one type of disease in conditions that were once considered entirely separate.
Fibromyalgia and the “Not Autoimmune” Gray Zone
Fibromyalgia is one of the more controversial conditions that falls under rheumatology’s purview. It causes widespread pain, fatigue, sleep disturbance, and cognitive difficulties, and it frequently overlaps with other conditions like irritable bowel syndrome and chronic fatigue syndrome. The driving mechanism is thought to be central sensitization, an amplified processing of pain signals in the central nervous system.14PubMed. Central sensitivity and fibromyalgia
Fibromyalgia isn’t autoimmune or autoinflammatory in the way that lupus or gout are. Standard blood tests and imaging usually come back normal. So why does a rheumatologist see these patients? Partly because fibromyalgia frequently coexists with autoimmune conditions, and partly because when patients arrive with widespread musculoskeletal pain, someone needs to determine whether it’s fibromyalgia, early lupus, an inflammatory arthritis, or something else entirely. Rheumatologists end up being the specialists best equipped to make those distinctions.
How Rheumatic Diseases Are Diagnosed
Diagnosing rheumatic diseases is notoriously tricky. Many conditions share overlapping symptoms, especially in their early stages. Blood tests help, but they’re far from definitive. The antinuclear antibody (ANA) test is a good example: it’s very sensitive, catching roughly 98% of people with autoimmune connective tissue disease, but its specificity is only about 75%, meaning that a positive ANA result can show up in perfectly healthy people and in many non-rheumatic conditions.15PubMed Central. Frequency of Repeating Antinuclear Antibody Testing: When Less Is More Combining different lab methods can improve accuracy.16PubMed. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases But a positive ANA result alone doesn’t mean you have an autoimmune disease, which is a misconception that causes a lot of unnecessary anxiety.
Imaging has become increasingly important. Musculoskeletal ultrasound can detect early signs of joint inflammation, including synovial thickening, increased blood flow, fluid buildup, and early bone erosions, sometimes before symptoms become clinically obvious.17PubMed Central. Advances in the Application of Musculoskeletal Ultrasound in the Diagnosis of Rheumatoid Arthritis: A Review MRI remains more sensitive for picking up the earliest changes, particularly for synovitis and tenosynovitis, but ultrasound is cheaper, faster, and can be done in the clinic during a routine visit, which gives it practical advantages.18PubMed Central. Do musculoskeletal ultrasound and magnetic resonance imaging identify synovitis and tenosynovitis at the same joints and tendons? A comparative study in early inflammatory arthritis and clinically suspect arthralgia Ultrasound has been especially valuable for seronegative rheumatoid arthritis, where the usual blood markers are absent and the diagnosis depends more heavily on detecting physical evidence of inflammation.
Getting to a Rheumatologist Can Take Too Long
One of the biggest practical problems in rheumatology is the gap between symptom onset and diagnosis. In several countries, patients with rheumatoid arthritis visit their primary care doctor a median of four times before being referred to a specialist, and the overall delay from first symptoms to diagnosis can stretch to a year.19BMJ Open / BMJ Publishing Group Ltd. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities That delay matters because the window for preventing irreversible joint damage in diseases like rheumatoid arthritis is relatively narrow. Early aggressive treatment leads to much better long-term outcomes than the same treatment started a year later.
Even after diagnosis, adherence to therapy varies widely. Estimates suggest that anywhere from 30% to 80% of patients don’t follow their treatment plans consistently, and up to half lack regular specialist follow-up.20BMJ Open / BMJ Publishing Group Ltd. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities Part of this is structural: there aren’t enough rheumatologists to go around in many regions, particularly rural areas. Part of it is that the medications used in rheumatology, many of which suppress the immune system, can feel intimidating to patients.
Modern Treatment and the Biologic Revolution
The treatment landscape in rheumatology has transformed over the past two to three decades. Older disease-modifying drugs like methotrexate remain the backbone of treatment for many conditions, but biologic therapies, which are engineered proteins that target specific immune molecules, have made it possible to control diseases that were once crippling. Tumor necrosis factor (TNF) inhibitors were the first major class to arrive, followed by drugs targeting other inflammatory pathways.
In a large meta-analysis comparing biologic and targeted synthetic disease-modifying drugs to conventional therapies in rheumatoid arthritis, the risk of death from any cause was similar between the two groups, with roughly 2.7% to 2.9% of patients dying during the study periods.21PubMed Central. Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis That finding is reassuring given initial concerns that suppressing the immune system aggressively might increase mortality. The benefits of these drugs in reducing joint destruction, pain, and disability have been substantial enough to shift the standard of care.
When Rheumatic Disease Starts in Childhood
Rheumatic diseases don’t wait for adulthood. Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions that begin before age sixteen, and its genetic architecture shows both overlap with and differences from adult inflammatory arthritis. Fine-mapping of the HLA region, the same stretch of chromosome 6 involved in ankylosing spondylitis, reveals that different JIA subtypes have genetic signatures that correspond to distinct adult diseases, suggesting that what we call “JIA” is really several different conditions grouped by age of onset.22Annals of the Rheumatic Diseases. Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases
Children with the polyarticular form of JIA are less likely to test positive for the antibodies typically associated with adult rheumatoid arthritis, and fewer than half meet the standard adult classification criteria for RA. They also tend to rely more heavily on TNF inhibitors: roughly half of polyarticular JIA patients were using these drugs in one cross-sectional analysis, compared with about 18% of adult RA patients. When children did use a TNF inhibitor, they stayed on it far longer, with a median duration of over four years versus less than a year for adults with RA.23PubMed Central. Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis A Cross-sectional Analysis of Clinical Features and Medication Use These differences matter clinically because they mean treatment strategies can’t simply be copied from adult guidelines.
Why Rheumatologists Care About Your Heart
One of the less intuitive aspects of rheumatology is its connection to cardiovascular disease. People with rheumatoid arthritis face an increased risk of accelerated atherosclerosis, the buildup of plaque in arteries that leads to heart attacks and strokes. Inflammatory molecules and autoantibodies associated with RA contribute to blood vessel damage and endothelial dysfunction, compounding whatever traditional risk factors (high cholesterol, high blood pressure, smoking) the patient already carries.24PubMed Central. Accelerated atherosclerosis in rheumatoid arthritis: a systematic review The systemic inflammation that defines RA doesn’t just affect joints; it accelerates the same vascular processes that cause heart disease in the general population, and it does so through multiple overlapping pathways.25PubMed. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis
This means that controlling inflammation in RA isn’t just about preventing joint damage; it may also reduce cardiovascular risk. Therapies that target the inflammatory burden, along with management of conventional risk factors like cholesterol and blood pressure, appear to improve vascular outcomes in RA patients.26PubMed Central. Accelerated atherosclerosis in rheumatoid arthritis: a systematic review This is why modern rheumatologists increasingly screen for cardiovascular risk and coordinate with cardiologists, turning what was once a purely joint-focused specialty into something more like whole-body immune medicine.
The Microbiome Connection
One of the more active frontiers in rheumatology research involves the trillions of bacteria that live in the gut and at other mucosal surfaces. There is a growing body of evidence linking the composition of the gut microbiome to rheumatoid arthritis risk and disease activity. The microbiome interacts extensively with immune cells, influencing both the T cell and B cell responses that drive autoimmune inflammation.27PubMed Central. Microbial Influences of Mucosal Immunity in Rheumatoid Arthritis Some studies have identified specific bacterial shifts in people who are at risk for developing RA but haven’t yet shown clinical symptoms, raising the possibility that the microbiome could eventually serve as an early warning signal or even a target for prevention.
The field hasn’t yet translated these findings into practical clinical tools. No probiotic has been proven to prevent or treat rheumatoid arthritis, and microbiome testing isn’t part of standard rheumatologic workups. But the research has reframed how scientists think about disease triggers: the old model of genetics plus some unknown environmental insult is giving way to a more nuanced picture where the microbes living inside us may be the environmental factor that tips genetically susceptible people into active disease. For a specialty that spent most of its history focused on what happens after the immune system goes wrong, the possibility of understanding why it goes wrong in the first place represents a meaningful shift in ambition.